
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom has demonstrated robust growth in both domestic and international markets, with international revenue increasing by 22% year-over-year, driven primarily by recent coverage wins in France and Canada. The company has effectively expanded its contribution from Type 2 diabetes (T2D) customers, achieving a 21% increase in domestic revenue, reinforcing its strong market penetration. Additionally, DexCom's upward revised sales guidance for the full year, now projected at $4.630B to $4.650B, coupled with favorable trends in remote monitoring and patient accessibility, indicates a promising trajectory for sustainable growth moving forward.
Bears say
DexCom's lowered profitability outlook and weak gross margins are indicative of underlying challenges within the company, as highlighted by the first declining quarter of new patient additions in some time. The revenue growth for sensors, while positive, was offset by a significant decline in hardware sales and concerns regarding quality issues, which may have adverse effects on future performance. Additionally, competitive pressures and operational risks, including escalating pricing competition and supply chain disruptions, further contribute to a negative outlook for DexCom’s stock.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares